A clinicopathological analysis of 40 cases of ovarian Sertoli–Leydig cell tumors

Gui, Ting; Cao, Dongyan; Shen, Keng; Yang, Jiaxin; Zhang, Yiwen; Yu, Qi; Wan, Xirun; Xiang, Yang; Xiao, Yu; Guo, Lanwei

doi:10.1016/j.ygyno.2012.07.114

Cited by 111 publications

(131 citation statements)

References 25 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…10 Gui ve ark.nın 43 yıllık periyod boyunca saptadık-ları 40 SLHT vakasından 11'i postmenopozal hasta olup, bunlardan beşinin endometriyal küretajları-nın sonucu düzensiz proliferatif endometriyumdur. 11 SLHT'ler, sıklıkla tek overi tutan, makroskobik olarak sarı-gri renkte, kapsüllü, ortalama boyutları 0,8-30 cm arasında değişen, kesit yüzeyleri yer yer solid, yer yer fibröz septumlarla ayrılmış kistik, kanama ve nekroz alanları içeren özellikte-dir. 3 Over SLHT'lerinin yaklaşık %60'ında solid ve kistik komponent birlikte görülmüştür.…”

Section: Discussionunclassified

Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor in a Postmenopausal Woman: Case Report

Sayar¹,

Canaz²,

Doğan³

et al. 2016

Turkiye Klinikleri J Gynecol Obst

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor in a Postmenopausal Woman: Case Report

Sayar¹,

Canaz²,

Doğan³

et al. 2016

Turkiye Klinikleri J Gynecol Obst

View full text Add to dashboard Cite

show abstract

“…The role of adjuvant therapy is still inconclusive. Although its effectiveness in preventing recurrence of the disease has not been demonstrated [12,17], some authors recommend adjuvant chemotherapy and longterm follow-up in patients with risk factors for recurrence [19]. Conservative surgery may be acceptable for young patients who wish to preserve fertility, although the tendency of poorly differentiated tumors to reappear is an issue that should be borne in mind [19,20].…”

Section: Discussionmentioning

confidence: 99%

Sertoli-Leydig tumor and male pseudohermaphroditism discovered during inguinal hernia surgery

et al. 2014

View full text Add to dashboard Cite

AbstractThe diagnosis of inguinal hernia is usually clinical and it is performed with high sensitivity and specificity. Very occasionally, it may be confused with other diseases (lymphadenopathy, testicular pathology,etc). We report a rare case of a 80-year-old woman with a clinical diagnosis of hernia, which was underwent surgery and a tumor from the hernia orifice was found. After histological analysis we discovered that the misdiagnosed hernia was actually a tumor on a rudimentary testis. After radiological, gynecological and cytogenetic assessment we obtained an unexpected diagnosis: Male psheudohermaphroditism and Sertoli-Leydigtumor (SLCT) development on the testis. Diagnostic guidance for disorders of sexual development is based almost entirely on pediatric experience and very few guidelines are available for adults. Male pseudohermaphroditism is an intersex condition in which the carriers show a phenotype that includes external female genitalia, but a male genetic and gonadal sex. SLCT are sex-cord stromal tumors which develop in ovary and very rarely in the testis, representing 0.1–0.5% of ovarian tumors and less than 0.2% of testicular tumors. Thus far 24 case have been reported in the literature in which SLCT tumor has developed on testis.

show abstract

“…The sex cord-stromal tumors are relative rare, comprising 5-8% of all ovarian neoplasms, and are subdivided further according to the cell of origin; less than half are androgen secreting (Table 2) (59, 60). The Sertoli-Leydig cell tumors (androblastomas) account for !0.5% of all ovarian tumors, and although can occur at any age, approximately one-fourth present after menopause (61,62). These tumors exhibit a variable composition of Sertoli, Leydig, and fibroblastic cells; androgenic manifestations are more common in the absence of heterologous elements and virilization is found in at least one-third of the patients (61,62,63).…”

Section: Androgen-secreting Ovarian Tumorsmentioning

confidence: 99%

“…The Sertoli-Leydig cell tumors (androblastomas) account for !0.5% of all ovarian tumors, and although can occur at any age, approximately one-fourth present after menopause (61,62). These tumors exhibit a variable composition of Sertoli, Leydig, and fibroblastic cells; androgenic manifestations are more common in the absence of heterologous elements and virilization is found in at least one-third of the patients (61,62,63). The Sertoli-Leydig cell tumors are of relatively large size, generally unilateral and are mainly confined to the ovary at the time of diagnosis; staging is described similarly to that of other ovarian cancers (62).…”

Section: Androgen-secreting Ovarian Tumorsmentioning

confidence: 99%

“…These tumors exhibit a variable composition of Sertoli, Leydig, and fibroblastic cells; androgenic manifestations are more common in the absence of heterologous elements and virilization is found in at least one-third of the patients (61,62,63). The Sertoli-Leydig cell tumors are of relatively large size, generally unilateral and are mainly confined to the ovary at the time of diagnosis; staging is described similarly to that of other ovarian cancers (62). These tumors are rarely malignant depending also on the degree of differentiation, while some may exhibit early recurrence following surgical resection.…”

Section: Androgen-secreting Ovarian Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause

Markopoulos

Kassi

Alexandraki

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Postmenopausal hyperandrogenism is a state of relative or absolute androgen excess originating from either the adrenals and/or the ovaries, clinically manifested as the appearance and/or increase in terminal hair growth or the development of symptoms/signs of virilization. In either settings, physicians need to evaluate such patients and exclude the presence of the relatively rare but potentially life-threatening underlying tumorous causes, particularly adrenal androgen-secreting tumors. It has been suggested that the rapidity of onset along with severity of symptom and the degree of androgen excess followed by relevant imaging studies may suffice to identify the source of excessive androgen secretion. However, up to date, there is no consensus regarding specific clinical and hormonal indices and/or imaging modalities required for diagnostic certainty. This is particularly relevant as the aging population is increasing and more cases of postmenopausal women with clinical/biochemical evidence of hyperandrogenism may become apparent. Furthermore, the long-term sequels of nontumorous hyperandrogenism in postmenopausal women in respect to cardiovascular morbidity and mortality still remain unsettled. This review delineates the etiology and pathophysiology of relative and absolute androgen excess in postmenopausal women. Also, it attempts to unravel distinctive clinical features along with specific hormonal cut-off levels and/or appropriate imaging modalities for the facilitation of the differential diagnosis and the identification of potential long-term sequels.

show abstract

A clinicopathological analysis of 40 cases of ovarian Sertoli–Leydig cell tumors

Cited by 111 publications

References 25 publications

Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor in a Postmenopausal Woman: Case Report

Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor in a Postmenopausal Woman: Case Report

Sertoli-Leydig tumor and male pseudohermaphroditism discovered during inguinal hernia surgery

MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause

Contact Info

Product

Resources

About